Publications
BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.
Note: To find a complete list of Publications, please see listing here.
Found 40 results
Filters: Keyword is Transplantation Conditioning [Clear All Filters]
“Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102.”, Am J Hematol, vol. 98, no. 2, pp. 229-250, 2022.
, “Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012.”, Transplant Cell Ther, vol. 28, no. 7, pp. 406.e1-406.e6, 2022.
, “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
, “Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients.”, Transplant Cell Ther, vol. 27, no. 10, pp. 879.e1-879.e3, 2021.
, “Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023.”, Transplant Cell Ther, vol. 27, no. 2, pp. 183.e1-183.e7, 2021.
, “Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.”, Transplant Cell Ther, vol. 27, no. 6, pp. 483.e1-483.e6, 2021.
, “Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.”, J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2021.
, “Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes.”, Transplant Cell Ther, vol. 28, no. 2, pp. 109.e1-109.e8, 2021.
, “Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.”, Biol Blood Marrow Transplant, vol. 26, no. 3, pp. 606-611, 2020.
, “Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.”, J Clin Oncol, vol. 38, no. 12, pp. 1273-1283, 2020.
, “Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation.”, Bone Marrow Transplant, vol. 55, no. 9, pp. 1810-1816, 2020.
, “A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703.”, Biol Blood Marrow Transplant, vol. 26, no. 12, pp. e305-e308, 2020.
, “Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.”, Biol Blood Marrow Transplant, vol. 26, no. 5, pp. e94-e100, 2020.
, “Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.”, Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2160-2166, 2019.
, “Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD.”, Bone Marrow Transplant, vol. 54, no. 3, pp. 490-493, 2019.
, “Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601.”, Biol Blood Marrow Transplant, vol. 25, no. 5, pp. e174-e178, 2019.
, “Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with ”, Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.
, “Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.”, Blood, vol. 132, no. 13, pp. 1438-1451, 2018.
, “Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial.”, Bone Marrow Transplant, vol. 53, no. 8, pp. 1038-1043, 2018.
, “Translation of Clinical Research into Practice: An Impact Assessment of the Results from the Blood and Marrow Transplant Clinical Trials Network Protocol 0201 on Unrelated Graft Source Utilization.”, Biol Blood Marrow Transplant, vol. 24, no. 11, pp. 2204-2210, 2018.
, “Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.”, Bone Marrow Transplant, vol. 52, no. 9, pp. 1300-1303, 2017.
, “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.”, J Clin Oncol, vol. 35, no. 11, pp. 1154-1161, 2017.
, “Pharmacogenetics of steroid-responsive acute graft-versus-host disease.”, Clin Transplant, vol. 31, no. 5, 2017.
, “Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.”, Biol Blood Marrow Transplant, vol. 23, no. 10, pp. 1714-1721, 2017.
, “Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.”, Bone Marrow Transplant, vol. 51, no. 12, pp. 1599-1601, 2016.
,